Surrozen Inks Strategic Partnership With Boehringer Ingelheim For Retinal Disease Candidate
- Surrozen Inc entered into a collaboration and license agreement with Boehringer Ingelheim to research and develop SZN-413 for retinal diseases.
- SZN-413 is a bi-specific antibody targeting Fzd4-mediated Wnt signaling designed using Surrozen's SWAP technology.
- It is currently being developed for the treatment of retinal vascular-associated diseases.
- In preclinical models of retinopathy, SZN-413 could potently stimulate Wnt signaling in the eye, induce normal retinal vessel regrowth, suppress pathological vessel growth, and reduce vascular leakage.
- Under the terms of the agreement, Boehringer Ingelheim will receive an exclusive, worldwide license to develop SZN-413 and other Fzd4-specific Wnt-modulating molecules for all purposes, including as a treatment for retinal diseases, for an upfront of $12.5 million.
- Surrozen will also be eligible to receive up to $586.5 million in milestone payments.
- After an initial joint research period, Boehringer Ingelheim will assume all development and commercial responsibilities.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.